Vaderis Therapeutics

News

Our round-up of venture capital financings in biotech this week features Vaderis, Aureka, Epicrispr, Infinimmune, and Boulevard Bio.

News

A trial of Vaderis' AKT inhibitor engasertib finds it could be the first effective treatment for rare disease hereditary haemorrhagic telangiectasia.

News

Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.